JP2017538659A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538659A5
JP2017538659A5 JP2017512982A JP2017512982A JP2017538659A5 JP 2017538659 A5 JP2017538659 A5 JP 2017538659A5 JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017538659 A5 JP2017538659 A5 JP 2017538659A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
group
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049221 external-priority patent/WO2016040505A1/en
Publication of JP2017538659A publication Critical patent/JP2017538659A/ja
Publication of JP2017538659A5 publication Critical patent/JP2017538659A5/ja
Pending legal-status Critical Current

Links

JP2017512982A 2014-09-10 2015-09-09 Ｓｍｙｄ阻害剤 Pending JP2017538659A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048773P 2014-09-10 2014-09-10
US62/048,773 2014-09-10
US201562146799P 2015-04-13 2015-04-13
US62/146,799 2015-04-13
PCT/US2015/049221 WO2016040505A1 (en) 2014-09-10 2015-09-09 Smyd inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020013314A Division JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤

Publications (2)

Publication Number Publication Date
JP2017538659A JP2017538659A (ja) 2017-12-28
JP2017538659A5 true JP2017538659A5 (enExample) 2018-10-18

Family

ID=55459528

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512982A Pending JP2017538659A (ja) 2014-09-10 2015-09-09 Ｓｍｙｄ阻害剤
JP2020013314A Pending JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤
JP2022118248A Pending JP2022163087A (ja) 2014-09-10 2022-07-25 Ｓｍｙｄ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020013314A Pending JP2020090520A (ja) 2014-09-10 2020-01-30 Ｓｍｙｄ阻害剤
JP2022118248A Pending JP2022163087A (ja) 2014-09-10 2022-07-25 Ｓｍｙｄ阻害剤

Country Status (13)

Country Link
US (4) US10266526B2 (enExample)
EP (1) EP3193600A4 (enExample)
JP (3) JP2017538659A (enExample)
KR (2) KR20230026515A (enExample)
CN (2) CN107072205B (enExample)
AU (1) AU2015315174B2 (enExample)
BR (1) BR112017004612A2 (enExample)
CA (1) CA2960275A1 (enExample)
EA (1) EA201790317A1 (enExample)
IL (2) IL250891A0 (enExample)
MX (2) MX2017002985A (enExample)
SG (2) SG10201901192TA (enExample)
WO (1) WO2016040505A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
WO2018030550A1 (en) 2016-08-09 2018-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds with an ror(gamma)t modulating activity
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
EP3592736A1 (en) * 2017-03-10 2020-01-15 Rutgers, the State University of New Jersey Indole derivatives as efflux pump inhibitors
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
US20200138827A1 (en) * 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
IL272379B2 (en) 2017-08-14 2025-11-01 Epizyme Inc Methods of treating cancer by inhibiting setd2
JP7627209B2 (ja) * 2018-08-14 2025-02-05 エピザイム，インコーポレイティド 置換インドール及びその使用方法
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
US20220389019A1 (en) * 2019-08-08 2022-12-08 Université De Strasbourg TrkB POSITIVE ALLOSTERIC MODULATORS
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods of using same
CN121695288A (zh) * 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法
EP4164622A4 (en) 2020-06-16 2024-09-11 Icahn School of Medicine at Mount Sinai SOX11 INHIBITORS FOR THE TREATMENT OF MANTLE CELL LYMPHOMA
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
CN114246851B (zh) * 2021-11-09 2024-01-26 澳门科技大学 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途
CN114702552B (zh) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 mTORC2抑制剂
WO2023192665A2 (en) * 2022-04-01 2023-10-05 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
GB2620976B (en) * 2022-07-28 2024-07-24 Jones Paul Amido-amine hardener
US20260200891A1 (en) * 2022-11-17 2026-07-16 Tenvie Therapeutics, Inc. Compounds, compositions, and methods
CN120882411A (zh) * 2022-11-17 2025-10-31 腾维治疗公司 化合物、组合物和方法
WO2024158863A1 (en) * 2023-01-25 2024-08-02 The Rockefeller University Sulfonamide-1h-pyrrole-2-carboxamide inhibitors of sars-cov-2 nsp14 methyltransferase and derivatives thereof
CN116327748B (zh) * 2023-04-21 2024-09-17 武汉科技大学 联合用药物在制备抗肿瘤药物中的用途
WO2025165834A1 (en) * 2024-01-31 2025-08-07 Ensem Therapeutics, Inc. Urea derivatives of tricyclic compounds, and compositions and methods thereof
WO2025264278A1 (en) * 2024-06-18 2025-12-26 Memorial Sloan-Kettering Cancer Center Erk2 degraders
WO2026006505A1 (en) * 2024-06-26 2026-01-02 Virginia Commonwealth University Compounds as nlrp3 inhibitors and compositions and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507846A (ja) * 1993-12-30 1997-08-12 スミスクライン・ビーチャム・コーポレイション フェニルメチルヘキサンアミドおよびその使用
WO1998022432A1 (en) * 1996-11-18 1998-05-28 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
EE200200119A (et) * 1999-09-21 2003-04-15 Astrazeneca Ab Kinasoliini derivaadid ja nende kasutamine ravimitena
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
EP1310491A1 (en) 2000-07-19 2003-05-14 Takeda Chemical Industries, Ltd. Method for producing 1-substituted-1,2,3-triazole derivative
AUPR034000A0 (en) * 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
EP1390034A4 (en) * 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JP2004175739A (ja) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd 医薬組成物
JP2004315395A (ja) * 2003-04-14 2004-11-11 Yamanouchi Pharmaceut Co Ltd 新規な安息香酸誘導体又はその塩
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
WO2005026112A2 (en) * 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
US7626030B2 (en) * 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
CA2555812A1 (en) * 2004-02-13 2005-09-01 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
EP1817025A2 (en) * 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
JP2008531673A (ja) * 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ 抗菌活性をもつアゼチジン及びピロールの三環式誘導体
BRPI0608659A2 (pt) * 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
US7273882B2 (en) * 2005-06-21 2007-09-25 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as β-secretase inhibitors
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
PE20071092A1 (es) * 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US20090253673A1 (en) * 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
WO2008016666A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008075196A1 (en) * 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
PE20091576A1 (es) * 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
JP5504259B2 (ja) * 2008-05-19 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション 第ｉｘａ因子阻害剤としての複素環式化合物
EP2307377A1 (en) * 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
AU2009289649B2 (en) * 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
KR101892575B1 (ko) * 2010-10-14 2018-08-31 제이더블유중외제약 주식회사 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
EP2648736A4 (en) * 2010-12-08 2015-04-29 Lycera Corp CYCLOALKYL GUANIDINE F1F0 ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
EP2532661A1 (en) * 2011-06-10 2012-12-12 Syngenta Participations AG Novel insecticides
CN103635474B (zh) * 2011-06-17 2016-04-27 巴斯利尔药物股份公司 三环抗生素
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
CN103877078B (zh) * 2012-12-20 2017-03-15 上海交通大学医学院 Senp2小分子抑制剂及其应用
JP2017527577A (ja) 2014-09-10 2017-09-21 エピザイム，インコーポレイティド 置換ピロリジン化合物
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3193609A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd

Similar Documents

Publication Publication Date Title
JP2020090520A5 (enExample)
JP2017528461A5 (enExample)
JP2017511801A5 (enExample)
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2017528464A5 (enExample)
US10889589B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
US9790210B2 (en) N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
AU2015330506B2 (en) EGFR inhibitor, and preparation and application thereof
RU2632908C2 (ru) Гетероциклическое производное и фармацевтическое средство
US9969694B2 (en) N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
CN112601747B (zh) 作为malt1抑制剂的吡唑衍生物
JP2017527577A5 (enExample)
JP2020503299A5 (enExample)
US20160280681A1 (en) N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US20190322660A1 (en) Smyd inhibitors
JP2011510995A5 (enExample)
JP2019519595A (ja) 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
MXPA05007990A (es) Compuestos de tienopirimidina y uso de los mismos.
CN104098551A (zh) 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
JP2017528460A5 (enExample)
JP2017527577A (ja) 置換ピロリジン化合物
JP2017527576A5 (enExample)